Obsessive-compulsive symptoms (OCS) are clinically important phenomena in schizophrenia patients. Lamotrigine has a modulating effect on glutamatergic neurotransmission relevant to pathophysiology of both schizophrenia and OCD. Efficacy and tolerability of lamotrigine in schizophrenia and schizoaffective patients with comorbid OCS were evaluated. In an 8-week, open-label trial, lamotrigine (25 mg/day for 1 week, 50 mg for 2 weeks, 100 mg for 2 weeks, 200 mg for 3 weeks) was added to ongoing psychotropic drug regimens in schizophrenia (N = 5) and schizoaffective disorder (N = 6) patients with clinically significant OCS [Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score > 16]. The Y-BOCS score for nine completers decreased significantly from baseline to week 8 (22.9 ± 6.1 vs 17.4 ± 3.6; t = 2.33, df = 1, P = 0.033). Five patients, all with schizoaffective disorder, were responders (≥35% decrease in Y-BOCS score). No significant changes were detected in schizophrenia symptom severity. Depressive symptoms, assessed with the Calgary Depression Rating Scale, improved significantly (6.4 ± 1.5 vs 4.0 ± 2.5; t = 3.19, df = 1, P = 0.013); this change positively correlated with OCS improvement (r = 0.69, P = 0.04). Lamotrigine was safe and well tolerated. Explicit evaluation of therapeutic efficacy of adjunctive lamotrigine in schizoaffective disorder patients with comorbid OCS merits further investigation.
Addington, D., Addington, J., Schissel, B. ( 1990) A depression rating scale for schizophrenics. Schizophr Res3: 247-251.
2.
Anand, A., Charney, DS, Oren, DA, Berman, RM, Hu, XS, Cappiello, A., et al. (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry57: 270-276.
3.
Andreasen, NC ( 1983) Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
4.
Andreasen, NC ( 1984) Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
5.
Chakrabarty, K., Bhattacharyya, S., Christopher, R., Khanna, S. ( 2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology30: 1735-1740.
6.
de Haan, L., Hoogenboom, B., Beuk, N., van Amelsvoort, T., Linszen, D. ( 2005) Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders . Can J Psychiatry50: 519-524.
7.
de Haan, L., Hoogeboom, B., Beuk, N., Wouters, L., Dingemans, PM, Linszen, DH ( 2006) Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull39: 25-30.
8.
Fenton, WS, McGlashan, TH ( 1986) The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry143: 437-441.
9.
Glick, I., Poyurovsky, M., Ivanova, O., Koran, LM ( 2008) Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms. J Clin Psychiatry (in press).
10.
Goff, DC, Keefe, R., Citrome, L., Davy, K., Krystal, JH, Large, C., et al. (2007) Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol27: 582-589.
11.
Goodman, WK, Price, LH, Rasmussen, SA, Mazure, C., Fleischmann, RL, Hill, CL, et al. (1989) The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry46: 1006-1011.
12.
Green, AI, Canuso, CM, Brenner, MJ, Wojcik, JD ( 2003) Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am26: 115-139.
13.
Javitt, DC ( 2007) Glutamate and Schizophrenia: Phencyclidine, N-Methyl-d-Aspartate Receptors, and Dopamine-Glutamate Interactions. Int Rev Neurobiol78: 69-108.
14.
Ketter, TA, Brooks, JO, Hoblyn, JC, Champion, LM, Nam, JY, Culver, JL, et al. (2008) Effectiveness of lamotrigine in bipolar disorder in a clinical setting. J Psychiatr Res43: 13-23.
15.
Ketter, TA, Calabrese, JR ( 2002) Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry63: 146-151.
16.
Kremer, I., Vass, A., Gorelik, I., Bar, G., Blanaru, M., Javitt, DC, et al. (2004) Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry56: 441-446.
17.
Krystal, JH, Perry Jr, EB, Gueorgieva, R., Belger, A., Madonick, SH, Abi-Dargham, A., et al. (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry62: 985-994.
18.
Kumar, TC, Khanna, S. ( 2000) Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry34: 527-528.
19.
Nechmad, A., Ratzoni, G., Poyurovsky, M., Meged, S., Avidan, G., Fuchs, C., et al. (2003) Obsessive-compulsive disorder in adolescent schizophrenia patients. Am J Psychiatry160: 1002-1004.
20.
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., et al. International Treatment Refractory OCD Consortium. (2002) Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol5: 181-191.
21.
Patil, ST, Zhang, L., Martenyi, F., Lowe, SL, Jackson, KA, Andreev, BV, et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med13: 1102-1107.
22.
Pittenger, C., Krystal, JH, Coric, V. ( 2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx3: 69-81.
23.
Poyurovsky, M., Bergman, J., Weizman, R. ( 2006) Obsessive-compulsive disorder in elderly schizophrenia patients. J Psychiatr Res40: 189-191.
24.
Poyurovsky, M., Dorfman-Etrog, P., Hermesh, H., Munitz, H., Tollefson, GD, Weizman, A. ( 2000) Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms. Int Clin Psychopharmacol15: 169-173.
25.
Poyurovsky, M., Fuchs, C., Weizman, A. ( 1999) Obsessive-compulsive disorder in patients with first-episode schizophrenia. Am J Psychiatry156: 1998-2000.
26.
Poyurovsky, M., Kriss, V., Weisman, G., Faragian, S., Schneidman, M., Fuchs, C., et al. (2005a) Familial aggregation of schizophrenia-spectrum disorders and obsessive-compulsive associated disorders in schizophrenia probands with and without OCD. Am J Med Genet B Neuropsychiatr Genet133: 31-36.
27.
Poyurovsky, M., Weizman, A., Weizman, R. ( 2004) Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs18: 989-1010.
28.
Poyurovsky, M., Weizman, R., Weizman, A., Koran, L. ( 2005b) Memantine for treatment-resistant OCD. Am J Psychiatry162: 2191-2192.
29.
Simpson, GM, Angus, JW ( 1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand212(Suppl): 11-19.
30.
Simpson, HB, Huppert, JD, Petkova, E., Foa, EB, Liebowitz, MR ( 2006) Response versus remission in obsessive-compulsive disorder . J Clin Psychiatry67: 269-276.
31.
Tibbo, P., Kroetsch, M., Chue, P., Warneke, L. ( 2000) Obsessive-compulsive disorder in schizophrenia. J Psychiatr Res34: 139-146.
32.
Tiihonen, J., Hallikainen, T., Ryynänen, OP, Repo-Tiihonen, E., Kotilainen, I., Eronen, M., et al. (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry54: 1241-1248.
33.
van Nimwegen, L., de Haan, L., van Beveren, N., Laan, W., van den Brink, W., Linszen, D. ( 2008) Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis . J Clin Psychopharmacol28: 214-218.
34.
Whiteside, SP, Port, JD, Deacon, BJ, Abramowitz, JS ( 2006) A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res146: 137-147.
35.
Zoccali, R., Muscatello, MR, Bruno, A., Cambria, R., Micò, U., Spina, E., et al. (2007) The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res93: 109-116.
